Showing results (21-30 of 43) with videos related to
Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2006
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B StudyPeter Paschka, Guido Marcucci, Amy S Ruppert, et al.International Journal of Oncology|October 9, 2002
Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461Sherif S Farag, Kellie J Archer, Krzysztof Mrózek, et al.Blood|December 9, 2015
Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in miceAparna Vasanthakumar, Stephen Arnovitz, Rafael Marquez, et al.Nature Communications|June 8, 2018
Author Correction: RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemiaJason X Cheng, Li Chen, Yuan Li, et al.Blood|May 4, 2006
Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B studyMichael D Radmacher, Guido Marcucci, Amy S Ruppert, et al.Archives of Pathology & Laboratory Medicine|February 23, 2017
Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of HematologyDaniel A Arber, Michael J Borowitz, Melissa Cessna, et al.Nature Communications|March 23, 2018
RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemiaJason X Cheng, Li Chen, Yuan Li, et al.Cancer|June 30, 2012
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802Wendy Stock, Jeffrey L Johnson, Richard M Stone, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2004
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621Jonathan E Kolitz, Stephen L George, Richard K Dodge, et al.Blood|June 5, 2010
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808Jonathan E Kolitz, Stephen L George, Guido Marcucci, et al.Pageof 5